Trials / Completed
CompletedNCT01313858
A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,613 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (Simponi®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Simponi® | |
| DRUG | Methotrexate | Given concomitantly with Simponi® |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2011-03-14
- Last updated
- 2016-11-01
- Results posted
- 2016-11-01
Source: ClinicalTrials.gov record NCT01313858. Inclusion in this directory is not an endorsement.